Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
In DMSO USD 117 In stock
USD 90 In stock
USD 270 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 44 Publications

8 Customer Reviews

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Panobinostat (LBH589) purchased from Selleck.

    HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

  • Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

    Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined by the WST-1 method.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

  • Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control, 20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

    p53(+/+) and (/) HCT116 cells were treated with TSA (1–5 lM),LBH589 (2–5 lM), valproate (2.5–5 mM), MS-275 (20 lM) and sodium butyrate (2 mM). TAp63 expression was compared in both cell lines after 24 h of treatment. Consistent with the above data, all HDAC inhibitors failed to induce significant levels of TAp63 in p53(/) HCT116 cells.

     

     

    Biochem Bioph Res Co 2009 391, 1748-1751. Panobinostat (LBH589) purchased from Selleck.

  • Western blot analysis of Acetyl-H3 and H3. 0-10μM Panobinostat was added.

    Dr.Zhang of Tianjin Medical University. Panobinostat (LBH589) purchased from Selleck.

    HDAC inhibitors induce p63a expression (A) HCT116 cells were treated with TSA (1 lM), LBH589 (2 lM), valproate (2.5 mM), MS-275 (20 lM) and sodium butyrate(2 mM) for 24 h. Expression of p63 was assessed by Western blotting with the H129 pan-anti-p63 antibody. Although TSA and LBH589 induced p63 efficiently, valproate, MS-275 and sodium butyrate were much less efficient. The lower panel shows the actin loading control. Arrow indicates TAp63. (B) The HDAC inhibitors used in this study are shown, grouped according to their structure and with their HDAC specificity. The efficiency of TAp63 expression is shown in the last column.

     

     

    Dr. Berna S. Sayan of Leicester University. Panobinostat (LBH589) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 M3vmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4qyU|AuOTBizszN NEn6UYoxNTRiZB?= M4nLd4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHX0bpozPjdyMke4OC=>
HepG2 M4GxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LscFAuOTBizszN NXq2eYtWOC12IHS= M4exVolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NYqzfVVqOjZ5MEK3PFQ>
HT29 NE[3ZlBHfW6ldHnvckBCe3OjeR?= M3uxNFUxyqCwTR?= NH;nR2kzPC15MjDo M2PNNYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhPDkEoHlCpC=> M13WRlI3PzB{N{i0
HepG2 NU\sflVLTnWwY4Tpc44hSXO|YYm= MmnwOVDDqG6P NFy5ZowzPC15MjDo NFjD[I5qdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|IHHmeIVzKDJ2wrDoxsA> NX3rSm1YOjZ5MEK3PFQ>
HCC827 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVe1M|cvPS9zMDDuUS=> M4r6WlczyqCq MljPSG1UVw>? MWHlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? NXPmWnVYOjZ4N{W0PFQ>
A549  M4DRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M325elExNzF3L{KwJI5O M1rxRlczyqCq MUfEUXNQ NYfU[45L\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= NWTEUnJyOjZ4N{W0PFQ>
NCI-H460  MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPjUZAyOC9{MD:zNEBvVQ>? NGrxZXQ4OsLiaB?= MX;EUXNQ MYDlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? NEHRVYUzPjZ5NUS4OC=>
J89GFP M1PRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\BSG1UV8Li M3rhcWVEPTB;NEmuPFUhyrFiMUKuOlUhdk1? MXuyOlU3OzV4OB?=
THP89GFP MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rrPGROW00EoB?= M3LtSWVEPTB;MUmuN|QhyrFiNj60N{BvVQ>? MX6yOlU3OzV4OB?=
SK-NEP-1 M1\IU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWSwMlAy6oDVMUCuNEDPxE1? M3;VTFI1KGh? MkLXSG1UV8Li NHTzNmtKSzVyPUe2MlM1KG6P NY\IWYhNOjZzN{[yNVk>
G401 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7DdnUxNjBz4pETNVAvOCEQvF2= NGXtZnIzPCCq M3rxRmROW00EoB?= MWnJR|UxRTF2Mz6wNkBvVQ>? MnzzNlYyPzZ{MUm=
SK-NEP-1 NXvrV2FYS2WubDDWbYFjcWyrdImgRZN{[Xl? NWn1cHRiPTBibl2= M4rrZlHjiJN2IHS= M{HXfmROW00EoB?= NHi5V25z\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? M2jCXFI3OTd4MkG5
G401 NX;3WFB2S2WubDDWbYFjcWyrdImgRZN{[Xl? NYfsepIxPTBibl2= NUfSU45pOeLCk{Sg[C=> M4fwWGROW00EoB?= NH;OTnRz\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? MWOyOlE4PjJzOR?=
SK-NEP-1 MV7BdI9xfG:|aYOgRZN{[Xl? NFuwWFU2OC9zMECgcm0> MXWyOEBp MknTSG1UV8Li NVTYeWZKcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mn7zNlYyPzZ{MUm=
G401 MnHURZBweHSxc3nzJGF{e2G7 NIjiSXY2OC9zMECgcm0> NEO1d|gzPCCq M1zEVGROW00EoB?= MonobY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnTJNlYyPzZ{MUm=
SK-NEP-1 M4TPcGZ2dmO2aX;uJGF{e2G7 NF\LN4I2OC9zMECgcm0> NXfURYtvOjRiaB?= NGnMXopFVVORwrC= MnO5d4hwf3NidHjlJIlv\HWldHnvckBw\iCGTlGg[pJi\22nboTheIlwdg>? MXOyOlE4PjJzOR?=
G401 NUXCRoMzTnWwY4Tpc44hSXO|YYm= MWG1NE8yODBibl2= MlvJNlQhcA>? NFP0fnRFVVORwrC= MlHud4hwf3NidHjlJIlv\HWldHnvckBw\iCGTlGg[pJi\22nboTheIlwdg>? MoLBNlYyPzZ{MUm=
SK-NEP-1 MlnPSpVv[3Srb36gRZN{[Xl? NYXCPXJUPTBxMUCwJI5O NXfs[XBSOjRiaB?= M2KxXGROW00EoB?= NWLjeVNIcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? MofpNlYyPzZ{MUm=
G401 MULGeY5kfGmxbjDBd5NigQ>? M1TEOlUxNzFyMDDuUS=> M{TyNVI1KGh? NXvkVlZHTE2VT9Mg NWPZeYc6cW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? M3T2TFI3OTd4MkG5
RPMI 8226 M{S1TGNmdGxiU4Xyeol3[WxiQYPzZZk> NUK2V5pbOi92L{[gcm0> NGX4dmc1QOLCiXi= M4\PXIlv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? MmTuNlYxODB{OUK=
OPM2 MWfD[YxtKFO3co\peoFtKEG|c3H5 MkHHNk81NzZibl2= MlXnOFjjiImq MV3pcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp MmDVNlYxODB{OUK=
U266 NWDGc|BsS2WubDDTeZJ3cX[jbDDBd5NigQ>? NHfrN2IzNzRxNjDuUS=> MlT6OFjjiImq MU\pcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp NVPu[llGOjZyMECyPVI>
H929 MmnwR4VtdCCVdYL2bZZidCCDc4PhfS=> MlXpNk81NzZibl2= MWS0PQKBkWh? NV;FXVl4cW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= Mkm0NlYxODB{OUK=
RPMI 8226  MWXBdI9xfG:|aYOgRZN{[Xl? MlXXOQKBkW6P NE[xXpgzPC92ODDo M4O4V4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MlXjNlYxODB{OUK=
HCC827 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfiNo4yOCCwTR?= MXi0PEBp MYrEUXNQ NYjuOndG\W6qYX7j[ZMh[2m|cHzheIlvKHOnboPpeIl3cXS7wrC= NWG4O41NOjV7NES2NVc>
NCI-H23 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj3NVAhdk1? MUm0PEBp NH:0[XdFVVOR MkXo[Y5p[W6lZYOgZ4l{eGyjdHnuJJNmdnOrdHn2bZR6yqB? NWnsPYFtOjV7NES2NVc>
AML3 Ml7ESpVv[3Srb36gRZN{[Xl? MVGwMVEh|ryP M2jWclI1yqCq M4DnTYlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MYOyOVYyOjl2MR?=
ML-1 MoXtSpVv[3Srb36gRZN{[Xl? NV;aOWZEOC1zIN88US=> NGPoPWkzPMLiaB?= MVrpcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NGP2ZY4zPTZzMkm0NS=>
RPMI-8226vr10  Moj2SpVv[3Srb36gRZN{[Xl? MnjFNE0yKM7:TR?= NIrYUJMzPMLiaB?= NVLqR20ycW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NVnRdVE6OjV4MUK5OFE>
ML-1 MY\GeY5kfGmxbjDBd5NigQ>? NH74WXgyKM7:TR?= M1rFWVI1yqCq MXnpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5JFQu\m:uZB?= MnvJNlU3OTJ7NEG=
RPMI-8226vr10  MUHGeY5kfGmxbjDBd5NigQ>? MWqxJO69VQ>? NVnORXJMOjUEoHi= MWHpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5JFIvPS2ob3zk MkizNlU3OTJ7NEG=
SK-N-BE (2) M1rD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLxT|BMOjUkgJno NVfDSIloUUN3ME2xNFQvOOLCidMx5qCKPy56IH7N M{jrO|I2OzB6OUG2
SK-N-BE (2), PAN  MK MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUSyOQKBkWh? MV3JR|UxRTFyND6w5qCKyrIkgJm3Mlghdk1? NV[3W5JXOjV|MEi5NVY>
SK-N-BE (2), MK  PAN NEi5WFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHPNlTjiImq NYrUSIp5UUN3ME2zPFIvOOLCidMx5qCKPDNwMjDuUS=> MlruNlU{ODh7MU[=
SK-N-AS NF7M[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q3fFI16oDLaB?= NIiwRldKSzVyPUO3MlHjiIoEsfMAjVIvPCCwTR?= NVjEbpJLOjV|MEi5NVY>
SK-N-DZ MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFqxfoozPOLCiXi= NFT4R4xKSzVyPUG3MlHjiIoEsfMAjVAvPCCwTR?= NVXKXFVPOjV|MEi5NVY>
Caki-1 MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[5VXFmOTBxMkWvOVAhdk1? M1TU[VQ5KGh? MoCzbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ MXeyOVI4QTF7MR?=
ACHN NECwdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn6OGJROTBxMkWvOVAhdk1? Mmi3OFghcA>? NWTye|ZmcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny M172PVI2Ojd7MUmx
769-P NFv2eXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjkNZIxOTBxMkWvOVAhdk1? NYC3SJZkPDhiaB?= M{HSVolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= M4H3OVI2Ojd7MUmx
786-O  NHG4bmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PxO|ExNzJ3L{WwJI5O NGrHcYM1QCCq M3n6UolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= M1XBZ|I2Ojd7MUmx
Caki-1 MWHBdI9xfG:|aYOgRZN{[Xl? MVW1NEBvVQ>? M{i3V|Q5KGh? MkXEbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? MnziNlUzPzlzOUG=
ACHN MV7BdI9xfG:|aYOgRZN{[Xl? NILES|c2OCCwTR?= Mn:5OFghcA>? MWLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? M3zi[|I2Ojd7MUmx
769-P NFfab5ZCeG:ydH;zbZMhSXO|YYm= M1;jU|UxKG6P NYq1V5BFPDhiaB?= NWf3[pRMcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= MofrNlUzPzlzOUG=
786-O  MUjBdI9xfG:|aYOgRZN{[Xl? NFfGSpU2OCCwTR?= MYG0PEBp M3HF[Ylv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ M1zrVFI2Ojd7MUmx
Caki-1 MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PPWlI2NzVyIH7N M3rrV|Q5KGh? NYHUcnBXTE2VTx?= Mn\obY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= M2q5OlI2OTd4M{W0
ACHN NHrY[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nIclI2NzVyIH7N NHPqc5k1QCCq MofVSG1UVw>? MX\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk M3;jVFI2OTd4M{W0
769-P NFnlWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{n5V|I2NzVyIH7N NWDoR3hWPDhiaB?= MkfsSG1UVw>? MlHXbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= MUKyOVE4PjN3NB?=
Caki-1 NH;tTYhEd2yxbomgSo9zdWG2aX;uJGF{e2G7 M2TvPFUxKG6P MknlO{0yPCCm NYDh[oVnTE2VTx?= NY\PSHQ5e3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB? MXuyOVE4PjN3NB?=
ACHN NIDHRohEd2yxbomgSo9zdWG2aX;uJGF{e2G7 M2W2W|UxKG6P MWe3MVE1KGR? NGXU[pRFVVOR NUTUeY9Me3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB? M2LWOlI2OTd4M{W0
769-P MkHqR49td267IF\vdo1ifGmxbjDBd5NigQ>? M4jLVFUxKG6P NWn3S|VjPy1zNDDk MYXEUXNQ NHfRWIR{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>? M1S1[lI2OTd4M{W0
Caki-1 MmnRRZBweHSxc3nzJGF{e2G7 NIDNcpg2OCCwTR?= NHH0VJA1QCCq MUDEUXNQ MljxbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MkP1NlUyPzZ|NUS=
ACHN NFfYOFdCeG:ydH;zbZMhSXO|YYm= MVi1NEBvVQ>? M3TFZlQ5KGh? MXnEUXNQ Mnz3bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M3\US|I2OTd4M{W0
769-P NHnrNIhCeG:ydH;zbZMhSXO|YYm= NE\aS5c2OCCwTR?= NHrCTJk1QCCq NIrocmpFVVOR NXH2dmJEcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MVeyOVE4PjN3NB?=
MDA-MB-231 MmXwUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 MVKxNOKhdk1? M1HZeFPDqGR? MXnEUXNQ NUjyNIFD[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg MWeyOFgyODR7Nx?=
BT-549 NUnEcVU{VW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 Mn;oNVDDqG6P M3P3OFPDqGR? MXnEUXNQ NXP6OVNz[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg M3uy[lI1QDFyNEm3
MCF-7  NHfXelROd3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl? MmHDNVDDqG6P NEH1SWw{yqCm NUS4VWFsTE2VTx?= M{XETIFtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= NHHT[WIzPDhzMES5Oy=>
MCF-7 MlnSSpVv[3Srb36gRZN{[Xl? M1TOU|UuPTBibl2= Mn3VNlQhcA>? NIfvbFJFVVOR M3T4Z5Jm\HWlZXSgeIhmKGyndnXsJI9nKGW6cILld5Nqd25ib3[gSXLPuSxiUGKgZY5lKE[xeFGxxsA> M3u3[FI1OzZ4NEC3
CTS NVjSO2FbSXCxcITvd4l{KEG|c3H5 Mni2NQKBmzRyIH7NxsA> MnLLOFghcA>? NHvNSIlqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M{X6S|I1OjR2NEK5
OCI-AML3  NITOWo1CeG:ydH;zbZMhSXO|YYm= NHHJd48x6oDVNECgcm3DqA>? NXHBVVhUPDhiaB?= NVLTZnlVcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MViyOFI1PDR{OR?=
U937 MUjBdI9xfG:|aYOgRZN{[Xl? MlmyNQKBmzRyIH7NxsA> MnnHOFghcA>? MX\pcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NETHXGgzPDJ2NESyPS=>
PC3 NHTHNGNCeG:ydH;zbZMhSXO|YYm= NXHEdnFROC1zMECgcm0> M1W4fVI1NzR6IHi= NFW1OpNqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NFf4cXgzPDF4M{KzNC=>
PC3-AR MmfJRZBweHSxc3nzJGF{e2G7 M4D6dVAuOTByIH7N MXGyOE81QCCq Ml;abY5lfWOnczDhdI9xfG:|aYOgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz NXT3UWFOOjRzNkOyN|A>
PC3 NWS5T5NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCwMVExOCCwTR?= MmWzNlQwPDhiaB?= MXvpcoR2[2W|IHHjZ5VufWyjdHnvckBw\iC|dXLHNUBxd3C3bHH0bY9v MoDtNlQyPjN{M{C=
PC3-AR NG\RN3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:4Z|AuOTByIH7N M1fsflI1NzR6IHi= MV3pcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJJRp\SCJMl2gdIhie2V? NWDWOpB6OjRzNkOyN|A>
PC3 NFO1WlNHfW6ldHnvckBCe3OjeR?= MUOwMVExOCCwTR?= NWXGRohJOjRiaB?= MkDod5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6= NULCN4ZrOjRzNkOyN|A>
PC3-AR MXzGeY5kfGmxbjDBd5NigQ>? M4nkdVAuOTByIH7N MYCyOEBp M3L3[5N2eHC{ZYPz[ZMh\XiycnXzd4lwdiCxZjDhZ5RqfmG2ZXSgRXRONCCDa4SgZY5lKEW{a{GvNkBxem:2ZXnu NUHFeWlGOjRzNkOyN|A>
OS-RC-2 NW\PUHhpS2WubDDWbYFjcWyrdImgRZN{[Xl? NUHoTllqOC1zMECwJI5O MYWyOE81QC95MjDo NEjkT3FFVVOR M{D5[IRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUOz[2NzOjRzNES3N|c>
OS-RC-2 NWf2TIFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nyR|UxKG6P NVizOHU5PDhiaB?= NUHaUlRpTE2VTx?= NH7sbFVqdmS3Y3XzJGczN01iYYLy[ZN1 Ml\ONlQyPDR5M{e=
OS-RC-2 M4PPbWFxd3C2b4Ppd{BCe3OjeR?= MofDOVAhdk1? NGHjWW41QCCq NUDRSJlITE2VTx?= NX[1e4RucW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M2q4elI1OTR2N{O3
SK-N-AS M{PZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn32NQKBmzhyIH7N MUG0PEBp M2K0PGlEPTB;MkeuOEBvVQ>? M1nuPFI1ODl6N{m5
SK-N-DZ Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;Hco8x6oDVOECgcm0> M2jWdFQ5KGh? MWjJR|UxRTJzLkmgcm0> NIjPWowzPDB7OEe5PS=>
SK-N-SH M1y4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWWw5qCUQDBibl2= MkS5OFghcA>? MnjaTWM2OD15Mj6zJI5O NVX1eIg2OjRyOUi3PVk>
SK-N-BE Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGw5qCUQDBibl2= Ml7iOFghcA>? NWr6OYN2UUN3ME23OU41KG6P NVj4dHRYOjRyOUi3PVk>
SK-N-AS MW\BdI9xfG:|aYOgRZN{[Xl? M4TLNFDjiJN6MDDuUS=> NEDVfoQ1QCCq M13RVJBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> NFnNR3MzPDB7OEe5PS=>
SK-N-DZ NV70WGVuSXCxcITvd4l{KEG|c3H5 NVj6foRkOOLCk{iwJI5O MkW3OFghcA>? NWHTNmljeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v NXH6[mhuOjRyOUi3PVk>
SK-N-SH NX[3SVJwSXCxcITvd4l{KEG|c3H5 MoXRNQKBmzRyIH7N M2WwPFQ5KGh? MYDwc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= NVLSO2N1OjRyOUi3PVk>
SK-N-BE NXTpVHJKSXCxcITvd4l{KEG|c3H5 MWew5qCUPDBibl2= NVT0Rnk1PDhiaB?= M4HvW5BwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> MoixNlQxQTh5OUm=
SK-N-AS MUjGeY5kfGmxbjDBd5NigQ>? NIXuWGgx6oDVOECgcm0> MmTNOFghcA>? M3TXW4lv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> NGjkXGQzPDB7OEe5PS=>
SK-N-DZ M2XmSGZ2dmO2aX;uJGF{e2G7 NUTxPJpEOOLCk{iwJI5O Mk\JOFghcA>? NGqzS3RqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR M2rFfFI1ODl6N{m5
SK-N-SH M1fZfGZ2dmO2aX;uJGF{e2G7 M1rMWVDjiJN2MDDuUS=> NYfDUos3PDhiaB?= NHWwXY5qdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR Mm[2NlQxQTh5OUm=
SK-N-BE NUDoNY4{TnWwY4Tpc44hSXO|YYm= NHfRNVQx6oDVNECgcm0> NFPRVIQ1QCCq M{TpZYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> NI[0XJEzPDB7OEe5PS=>
HCC-LM3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXqzUm46OS1zMECwJI5O NWPJboRHOjRxNEivO|IhcA>? Mm\ZSG1UVw>? MWjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1jjdlI1ODl|OUW2
HepG2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLsNU0yODByIH7N M2[yeFI1NzR6L{eyJIg> MXzEUXNQ NE\sVY1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NHP5[I4zPDB7M{m1Oi=>
SMMC-7721 NYH6eYZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDDUnkyNTFyMECgcm0> Mmr3NlQwPDhxN{KgbC=> MYPEUXNQ MmWxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4PSVFI1ODl|OUW2
HCC-LM3 MmTrRZBweHSxc3nzJGF{e2G7 NGj2[YM2OCCwTR?= NG[wd3g1QCCq Mm\JSG1UVw>? NEC1eIRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? MkXONlQxQTN7NU[=
HepG2 M4rDVGFxd3C2b4Ppd{BCe3OjeR?= M2fkV|UxKG6P MVi0PEBp MY\EUXNQ M1rSTYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 NYDKOJdDOjRyOUO5OVY>
SMMC-7721 M1\keGFxd3C2b4Ppd{BCe3OjeR?= MlrPOVAhdk1? NEDJRlQ1QCCq MlTvSG1UVw>? NXjWXlg3cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? NYXsUJF3OjRyOUO5OVY>
HCC-LM3 M4n3O2Z2dmO2aX;uJGF{e2G7 M2frZ|UxNzFyMDDuUS=> NWfNZY91OjRiaB?= MmPlSG1UVw>? NVn3T2Z2\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> NYC4[GdNOjRyOUO5OVY>
HepG2 M1HSOmZ2dmO2aX;uJGF{e2G7 M1TjTFUxNzFyMDDuUS=> M13JcFI1KGh? MVrEUXNQ MXfk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi MofINlQxQTN7NU[=
SMMC-7721 MofTSpVv[3Srb36gRZN{[Xl? M{jpRVUxNzFyMDDuUS=> NXPhOW9sOjRiaB?= Ml7NSG1UVw>? NWr0eIR{\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> MV[yOFA6Ozl3Nh?=
HCC-LM3 NHPGW|RHfW6ldHnvckBCe3OjeR?= NUntd4JEPTBxMUCwJI5O MkLQNlQhcA>? M4TWbWROW09? M2\XfYRwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25? MUOyOFA6Ozl3Nh?=
HepG2 MYnGeY5kfGmxbjDBd5NigQ>? NXG3SIVJPTBxMUCwJI5O NWnV[4xNOjRiaB?= MXvEUXNQ M4DCT4Rwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25? NIDQS3gzPDB7M{m1Oi=>
SMMC-7721 NUTtZ4xMTnWwY4Tpc44hSXO|YYm= NGnGOYI2OC9zMECgcm0> NIm1SnYzPCCq MlizSG1UVw>? Mo\l[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? MX[yOFA6Ozl3Nh?=
FaDu MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfDTJVOOTBy4pEFcm0> NFPSPFU5NzFyL{GyJIg> MW\kbZNxdGG7ZXSgZUB{cWewaX\pZ4FvfCCjbnSgdJJwdG:wZ3XkJGczN01iYYLy[ZN1KGG2IEigZY5lKDF{4pEFbEBxd3O2IILlcIVie2V? NHXYSHQzPDB{NkS4Ni=>
FaDu MlnFSpVv[3Srb36gRZN{[Xl? NIfRO3YyODEkgJXuUS=> NFWyTYkzNzRxOD:xNkBp M2fRcolv\HWlZXSgdFIyX2GoMT;DbZAyyqCneIDy[ZN{cW:w NHrJO4MzPDB{NkS4Ni=>
PC-3  M2HxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILB[IcxNTFyIN88US=> MWGyOE81QC95MjDo NYfvdYx5cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MnnCNlM6QTF{MU[=
LNCaP MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUmwMVUh|ryP Mn\xNlQwPDhxN{KgbC=> M4jZeIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWHMfoE2OjN7OUGyNVY>
RWPE-1  MoDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3BNWIxNTJyIN88US=> MW[yOE81QC95MjDo MVzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmnYNlM6QTF{MU[=
Capan-1 NVLoT3NNTnWwY4Tpc44hSXO|YYm= M2XSVVI2NzVyL{GwNEBvVQ>? MWG4M|I1NzR6IHi= MVzEUXNQ NVvXdYFV\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> MnjVNlM6OjJ6OE[=
L3.6pl MXXGeY5kfGmxbjDBd5NigQ>? NFPYeoIzPS93MD:xNFAhdk1? MVS4M|I1NzR6IHi= MXTEUXNQ M1nK[4Rwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= Mn3sNlM6OjJ6OE[=
CFPAC-1  MkPISpVv[3Srb36gRZN{[Xl? NWDaNG1tOjVxNUCvNVAxKG6P MoXDPE8zPC92ODDo MXjEUXNQ M3H6XIRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= NGSyUVIzOzl{Mki4Oi=>
Capan-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnscFIzPS93MD:xNFAhdk1? MY[0PEBp NHvKZYdFVVOR NHG1R3lz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVjZ[3ZXOjN7MkK4PFY>
L3.6pl NInPOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj6R4k4OjVxNUCvNVAxKG6P MYG0PEBp NV72U3dxTE2VTx?= MWPy[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MnjMNlM6OjJ6OE[=
CFPAC-1  NXvnfYg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYeyOU82OC9zMECgcm0> M4jLeVQ5KGh? MmOySG1UVw>? NU\RbXd{emWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NV\uOJd2OjN7MkK4PFY>
Capan-1 M37FeGFxd3C2b4Ppd{BCe3OjeR?= M{K4RlI2NzVyL{GwNEBvVQ>? NFewZoY1QCCq NHXZflNFVVOR NFPnTYRqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MlPQNlM6OjJ6OE[=
L3.6pl MkXRRZBweHSxc3nzJGF{e2G7 NGHQVVIzPS93MD:xNFAhdk1? MoTPOFghcA>? M1uzVmROW09? MV3pcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Ml3iNlM6OjJ6OE[=
CFPAC-1  MkXyRZBweHSxc3nzJGF{e2G7 MlezNlUwPTBxMUCwJI5O NGTPNW81QCCq MUTEUXNQ NWrNeXlwcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NYDibotTOjN7MkK4PFY>
HN22 MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXx[GNkOC1{MDDuUS=> MXOyOE81QCCq NYLWRWI{TE2VTx?= MlPVbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> NWfMZYJZOjN6N{eyN|U>
HSC4  NF7mXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXO[WgxNTJyIH7N NYHGNoRjOjRxNEigbC=> MV3EUXNQ M4\vT4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> NWj0NY4zOjN6N{eyN|U>
HN22 M2\ES2Fxd3C2b4Ppd{BCe3OjeR?= MoLCNE0zOCCwTR?= NH3ZZ2g1QCCq MVHEUXNQ NV:5dnA2cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MlvRNlM5Pzd{M{W=
HSC4  NGrMbHZCeG:ydH;zbZMhSXO|YYm= M1jnOVAuOjBibl2= M2i2bFQ5KGh? NXHG[GE2TE2VTx?= M1rVNIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NGKxXmYzOzh5N{KzOS=>
HN22 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DSRVAuOjBibl2= NEWxeZg1QCCq M4jJ[mROW09? MmXCbY5lfWOnczDHNUBxcGG|ZTDj[YxtKGO7Y3zlJIFzemW|dNMg NXzqZWZiOjN6N{eyN|U>
HSC4  MkDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6wMVIxKG6P MXq0PEBp NIHqZXdFVVOR M2L3fYlv\HWlZYOgS|EheGijc3WgZ4VtdCCleXPs[UBienKnc4VCpC=> NHW5W|kzOzh5N{KzOS=>
HN22 NXTu[nZlTnWwY4Tpc44hSXO|YYm= NFzncZExNTJyIH7N MYi0PEBp MkS3SG1UVw>? NFzMd2Z{fXCycnXzd4V{KFOyMTDlfJBz\XO|aX;uxsA> NGTSR|QzOzh5N{KzOS=>
HSC4  NGW0OmtHfW6ldHnvckBCe3OjeR?= MkDBNE0zOCCwTR?= MlraOFghcA>? M{f5OGROW09? NGm0[YF{fXCycnXzd4V{KFOyMTDlfJBz\XO|aX;uxsA> Mlu0NlM5Pzd{M{W=
Cal62 Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jacGlEPTB;M{OgxtEhPCCwTR?= NIS1dFEzOzh{NEC2OC=>
Hth7 NV;LWWFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1K1dGlEPTB;MUWgxtEhOiCwTR?= MnvSNlM5OjRyNkS=
Hth83 NGPpWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTN2INMxJFUhdk1? NI\o[W8zOzh{NEC2OC=>
C643 NVvS[WhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrVNpBKSzVyPUexJOKyKDFyIH7N MWWyN|gzPDB4NB?=
SW1736 M3;HSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\uTWM2OD1|NTFCtUA5KG6P MWKyN|gzPDB4NB?=
T241 M1:1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrRTVNUUUN3ME22OUDDuSB5IH7N MXOyN|gzPDB4NB?=
T351 NWPUZ4pyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrFbVFKSzVyPUWwJOKyKDFyIH7N M1TVUlI{QDJ2ME[0
BHP2-7 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jTcGlEPTB;M{egxtEhPiCwTR?= NWTB[|d6OjN6MkSwOlQ>
T238 M4jqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrTTXNKSzVyPUGsOVAxKMLzIEKwNEBvVQ>? NUm5TXJDOjN6MkSwOlQ>
HCT8 NI\1NpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zXS|czKGh? M{PUUWROW09? MkPOTWM2OD1zMj655qCKyrIkgJmxMlkhdk1? NI[xNoMzOzJ7OUO4PC=>
H630 NWTZbIhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TLUVczKGh? NEPPOmpFVVOR MmTlTWM2OD1zMj605qCKyrIkgJmzMlEhdk1? M4PaPFI{Ojl7M{i4
cH630 5-FU-res MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILBeJU4OiCq M{P6Z2ROW09? NVfUS|lKUUN3ME2xOU426oDLwsJihKkyNjJibl2= MonuNlMzQTl|OEi=
HCT116 NY\FdYhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX4O|IhcA>? M1rVXmROW09? M1KzXWlEPTB;MUCuO-KBkcLz4pEJNk4zKG6P M{jh[FI{Ojl7M{i4
HCT116 p53−/− NUXTTJNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fleVczKGh? MkXoSG1UVw>? MoHJTWM2OD16LkdihKnDueLCiUGuO{BvVQ>? MoWxNlMzQTl|OEi=
dHCT116 p21−/− MofHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILDRo84OiCq M4HL[2ROW09? NW\tSWFKUUN3ME21MlnjiIoEsfMAjVEvOyCwTR?= MWmyN|I6QTN6OB?=
HT29 NHjHenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nsNlczKGh? MorJSG1UVw>? MmC0TWM2OD1zNj6z5qCKyrIkgJmyMlMhdk1? MmewNlMzQTl|OEi=
LoVo M3v5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7IO|IhcA>? M{jhS2ROW09? M3rXNWlEPTB;NT6x5qCKyrIkgJmwMlYhdk1? NVPzdIJTOjN{OUmzPFg>
RKO MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf1c|JzPzJiaB?= NUjqNZdvTE2VTx?= NUnhbZlVUUN3ME23MlnjiIoEsfMAjVIvOiCwTR?= M2fUc|I{Ojl7M{i4
SW480 M{nsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP4ZZpmPzJiaB?= NXvPOG15TE2VTx?= M2fwUWlEPTB;MUeuOgKBkcLz4pEJNE45KG6P MViyN|I6QTN6OB?=
eSW620 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX63NkBp M1fHZWROW09? NULkPVBGUUN3ME25MlHjiIoEsfMAjVIvOSCwTR?= NV3NU3NEOjN{OUmzPFg>

... Click to View More Cell Line Experimental Data

In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+48% PEG 300+2% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02802163 Not yet recruiting Multiple Myeloma H. Lee Moffitt Cancer Center and Research Institute|Novartis|Amgen September 2016 Phase 1|Phase 2
NCT02756663 Not yet recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis June 2016 Phase 2
NCT02722941 Recruiting Multiple Myeloma H. Lee Moffitt Cancer Center and Research Institute|Novartis Pharmaceuticals June 2016 Phase 2
NCT02471430 Recruiting HIV Infection Massachusetts General Hospital|Novartis|Genentech, Inc. May 2016 Phase 1|Phase 2
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 2016 Phase 2
NCT02717455 Recruiting Glioma Pediatric Brain Tumor Consortium March 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID